Key statistics dashboard for Curis, Inc. (CRIS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Stock Data
| Price | $1.12 |
| Market Cap | $2M |
| Enterprise Value | -$2.4M |
| Beta | 3.14 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.08 |
| Price / Book | 0.51 |
| P/S | 0.51 |
| EV/EBITDA | 0.11 |
| EV/Sales | -0.55 |
| EV/FCF | 0.08 |
| P/FCF | -0.07 |
| Earnings Yield | -884.24% |
| FCF Yield | -1401.27% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.28% |
| EBIT Margin | -508.41% |
| EBITDA Margin | -506.24% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
| Return on Equity | -1035.26% |
| Return on Assets | -111.51% |
| Return on Invested Capital | -567.17% |
| Return on Capital Employed | -679.00% |
Financial Health
| Current Ratio | 0.49 |
| Quick Ratio | 0.49 |
| Cash Ratio | 0.41 |
| Debt / Equity | 0.22 |
| Debt / Assets | 5.50% |
| Net Debt / EBITDA | 0.21 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -92.32 |
Per-Share Data
| Revenue per share | 2.02 |
| Book Value per share | 2.20 |
| Cash per share | 2.63 |
| FCF per share | -14.32 |
| Tangible Book Value per share | -2.01 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 0.89 |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks